Beraprost

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Beraprost
Structure of Beraprost.png
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
Pharmacokinetic data
Bioavailability 50–70%
Metabolism Unknown
Biological half-life 35–40 minutes
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C24H30O5
Molar mass 398.492 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Beraprost is a pharmaceutical drug used in several Asian countries, including Japan and South Korea, as a vasodilator and antiplatelet agent.[1] It is classified as a prostacyclin analog.[1][2]

It has been studied for the treatment of pulmonary hypertension and for use in avoiding reperfusion injury.

Clinical pharmacology[edit]

As an analog of prostacyclin PGI2, beraprost affects vasodilation, which in turn lowers blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration[edit]

Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.

References[edit]

  1. ^ a b "Beraprost". drugs.com. 
  2. ^ Melian EB, Goa KL (2002). "Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension". Drugs. 62 (1): 107–33. doi:10.2165/00003495-200262010-00005.